Resistant Hypertension, Secondary Hypertension, and Hypertensive Crises: Diagnostic Evaluation and Treatment

Cardiology Clinics

Volumn 28, Issue 4, 2010, Pages 639-654

  Acelajado, Maria Czarina ^a   Calhoun, David A ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Diagnosis; Malignant hypertension; Resistant hypertension; Secondary hypertension; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CYCLOOXYGENASE 2 INHIBITOR; DIAZOXIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRILAT; GLYCERYL TRINITRATE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LABETALOL; MINERALOCORTICOID ANTAGONIST; MINOXIDIL; NICARDIPINE; NITROPRUSSIDE SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RENIN INHIBITOR; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VERAPAMIL;

ADD ON THERAPY; ANGINA PECTORIS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BRADYCARDIA; BREAST TENDERNESS; BRONCHOSPASM; CARDIOVASCULAR RISK; CAROTID SINUS PRESSORECEPTOR REFLEX; CATHETER ABLATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; ELECTROSTIMULATION THERAPY; EMERGENCY TREATMENT; ERECTILE DYSFUNCTION; FLUID RETENTION; FLUSHING; GYNECOMASTIA; HEART BLOCK; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOTENSION; INTRACRANIAL PRESSURE; KIDNEY FAILURE; KIDNEY FUNCTION TEST; KINESIOTHERAPY; LIBIDO DISORDER; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MENSTRUAL IRREGULARITY; METHEMOGLOBINEMIA; MORBIDITY; MORTALITY; MUSCLE TWITCH; NAUSEA; NAUSEA AND VOMITING; OPTIMAL DRUG DOSE; ORGAN INJURY; ORTHOSTATIC HYPOTENSION; PAIN; PATIENT COMPLIANCE; PHOTOSENSITIVITY; PRESCRIPTION; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; REFLEX TACHYCARDIA; RENOVASCULAR HYPERTENSION; REVIEW; RISK FACTOR; RISK REDUCTION; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SLEEP APNEA SYNDROME; SODIUM RESTRICTION; SYMPATHECTOMY; TACHYCARDIA; VOMITING; WHITE COAT HYPERTENSION;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIAGNOSIS, DIFFERENTIAL; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; HYPERTENSION, MALIGNANT; INFUSIONS, INTRAVENOUS; INFUSIONS, INTRAVENTRICULAR; RISK FACTORS;

EID: 77957735956     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2010.07.002     Document Type: Review

References (87)

1. Global health risks: mortality and burden of disease attributable to selected major risks 2004, World Health Organization, Geneva (Switzerland), Available at, Accessed December 23, 2009. http://www.who.int/healthinfo/global_burden_disease/global_health_risks/en/index.html.
2. Cutler J.A., Sorlie P.D., Wolz M., et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008, 52:818-827.
3. Whelton P.K., He J., Appel L.J., et al. Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program. JAMA 2002, 288:1882-1888.
4. Oparil S., Zaman M.A., Calhoun D.A. Pathogenesis of hypertension. Ann Intern Med 2003, 139:761-776.
5. Young J.H., Klag M.J., Muntner P., et al. Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP). J Am Soc Nephrol 2002, 13:2776-2782.
6. Hsu C.Y., McCulloch C.E., Darbinian J., et al. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005, 165:923-928.
7. Lloyd-Jones D., Adams R., Carnethon M., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics 2009 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:e21-181.
8. Campese V.M., Mitra N., Sandee D. Hypertension in renal parenchymal disease: why is it so resistant to treatment?. Kidney Int 2006, 69:967-973.
9. Centers for Disease Control and Prevention (CDC) Prevalence of chronic kidney disease and associated risk factors: United States, 1999-2004. MMWR Morb Mortal Wkly Rep 2007, 56:161-165.
10. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002, 39:S1-266.
11. National Kidney Foundation K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43:S1-268.
12. Nishizaka M.K., Zaman M.A., Green S.A., et al. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 2004, 109:2857-2861.
13. Lombes M., Farman N., Bonvalet J.P., et al. Identification and role of aldosterone receptors in the cardiovascular system. Ann Endocrinol (Paris) 2000, 61:41-46.
14. Marney A.N., Brown N.J. Aldosterone and end-organ damage. Clin Sci 2007, 113:267-278.
15. Rayner B.L., Opie L.H., Davidson J.S. The aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J 2000, 90:394-400.
16. Funder J.W., Carey R.M., Fardella C., et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008, 93:3266-3281.
17. Nishizaka M.K., Pratt-Ubunama M., Zaman M.A., et al. Validity of plasma aldosterone to renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 2005, 18:805-812.
18. Calhoun D.A., Nishizaka M.K., Zaman M.A., et al. High prevalence of primary aldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892-896.
19. Benchetrit S., Bernheim J., Podjarny E. Normokalemic hyperaldosteronism in patients with resistant hypertension. Isr Med Assoc J 2002, 4:17-20.
20. Garovic V.D., Kane G.C., Schwartz G.L. Renovascular hypertension: balancing the controversies in diagnosis and treatment. Cleve Clin J Med 2005, 72:1135-1147.
21. Nieto F.J., Young T.B., Lind B.K., et al. Sleep Heart Health Study. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. JAMA 2000, 283:1829-1836.
22. Ramachandran S.K., Josephs L.A. A meta-analysis of clinical screening tests for obstructive sleep apnea. Anesthesiology 2009, 110:928-939.
23. Haentjens P., Meerhaeghe A.V., Moscariello A.V., et al. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome. Arch Intern Med 2007, 167:757-765.
24. Nieman L.K., Biller B.M., Findling J.W., et al. The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol 2008, 93:1526-1540.
25. Eisenhofer G., Siegert G., Kotzerke J., et al. Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas. Horm Metab Res 2008, 40:329-337.
26. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51:1403-1419.
27. Furberg C.D., Wright J.T., Davis B.R., et al. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotension converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 2002, 288:2981. 2977.
28. Garg J.P., Elliott W.J., Folker A., et al. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005, 18:619-626.
29. Leotta G., Rabbia F., Canade A., et al. Characteristics of the patients referred to a Hypertension Unit between 1989 and 2003. J Hum Hypertens 2008, 22:119-121.
30. Pierdomenico S.D., Lapenna D., Bucci A., et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant and true resistant hypertension. Am J Hypertens 2005, 18:1422-1428.
31. Muxfeldt E.S., Bloch K.V., Nogueira A.R., et al. Twenty four hour ambulatory blood pressure monitoring pattern of resistant hypertension. Blood Press Monit 2003, 8:181-185.
32. Veglio F., Rabbia F., Riva P., et al. Ambulatory blood pressure monitoring and clinical characteristics of the true and white-coat resistant hypertension. Clin Exp Hypertens 2001, 23:203-211.
33. Muxfeldt E.S., Cardoso C.R., Salles G.F. Prognostic value of nocturnal blood pressure reduction in resistant hypertension. Arch Intern Med 2009, 169:874-880.
34. Verdecchia P., Schillaci G., Borgioni C., et al. Ambulatory pulse pressure. A potent predictor of total cardiovascular risk in hypertension. Hypertension 1998, 32:983-988.
35. Gillman M.W., Kannel W.B., Belanger A., et al. Influence of heart rate on mortality among patients with hypertension: the Framingham Heart Study. Am Heart J 1993, 125:1148-1154.
36. Ostchega Y., Dillon C.F., Hughes J.P., et al. Trends in hypertension prevalence, awareness, treatment and control in older US adults: data from the National Health and Nutrition Examination Survey 1998-2004. J Am Geriatr Soc 2007, 55:1056-1065.
37. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003, 289:2560-2572.
38. Lloyd-Jones D.M., Evans J.C., Larson M.G., et al. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000, 36:594-599.
39. Lloyd-Jones D.M., Evans J.C., Larson M.G., et al. Treatment and control of hypertension in the community: a prospective analysis. Hypertension 2002, 40:640-646.
40. Pratt-Ubunama M.N., Nishizaka M.K., Boedefeld R.L., et al. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007, 131:453-459.
41. Logan A.G., Perlikowski S.M., Mente A., et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001, 19:2271-2277.
42. Goncalves S.C., Martinez D., Gus M., et al. Obstructive sleep apnea and resistant hypertension. A case control study. Chest 2007, 132:1858-1862.
43. Gallay B.J., Ahmad S., Xu L., et al. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001, 37:699-705.
44. Eide I.K., Torjesen P.A., Drolsum A., et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004, 22:2217-2226.
45. Štrauch B., Zelinka T., Hampf M., et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003, 17:349-352.
46. Calhoun D.A., Nishizaka M.K., Zaman M.A., et al. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004, 125:112-127.
47. Saelen M.G., Prøsch L.K., Gudmundsdottir H., et al. Controlling systolic blood pressure is difficult in patients with diabetic kidney disease exhibiting moderate-to-severe reductions in renal function 2005, Blood Press, 14:170-6.
48. Gaddam K.K., Nishizaka M.K., Pratt-Ubunama M.N., et al. Characterization of resistant hypertension. Association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008, 168:1159-1164.
49. Sartori M., Calo L.A., Mascagna V., et al. Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens 2006, 19:373-379.
50. Pimenta E., Gaddam K.K., Pratt-Ubunama M.N., et al. Aldosterone excess and resistance to 24 hour blood pressure control. J Hypertens 2007, 25:2131-2137.
51. Pickering T.G. Principles and techniques of blood pressure measurement. Cardiol Clin 2002, 20:207-223.
52. Caro J.J., Speckman J.L., Salas M., et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999, 160:41-46.
53. Ogedegbe G., Schoenthaler A. A systematic review of the effects of home blood pressure monitoring on medication adherence. J Clin Hypertens 2006, 8:174-180.
54. Stason W.B., Shepard D.S., Perry H.M., et al. Effectiveness and costs of veterans affairs hyper-tension clinics. Med Care 1994, 32:1197-1215.
55. Burnier M., Santschi V., Favrat B., et al. Monitoring compliance in resistant hypertension: an important step in patient management. J Hypertens 2003, 31:S37-S42.
56. De Souza W.A., Yugar-Toledo J.C., Bergsten-Mendes G., et al. Effect of pharmaceutical care on blood pressure and health related quality of life in patients with resistant hypertension. Am J Health Syst Pharm 2007, 64:1955-1961.
57. Pickering T.G., White W.B. When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens 2008, 2:119-124.
58. Rodrigues C.S., Bloch K.V., Noguiera A.R. Office blood pressure and 24-h ambulatory blood pressure measurements: high proportion of disagreement in resistant hypertension. J Clin Epidemiol 2009, 62:745-751.
59. Grossman E., Messerli F.H. Secondary hypertension: interfering substances. J Clin Hypertens (Greenwich) 2008, 10:556-566.
60. Chasan-Taber L., Willett W.C., Manson J.E., et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996, 94(3):483-489.
61. Frishman W.H. Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol 2002, 89:18D-25D.
62. Ishiguro C., Fukita T., Omori T., et al. Assessing the effects of non-steroidal anti-inflammatory drugs on anti-hypertensive drug therapy using post-marketing surveillance database. J Epidemiol 2008, 18(3):119-124.
63. Avancini F., Palumbo G., Alli C., et al. Effects of low-dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients. Am J Hypertens 2000, 13:611-616.
64. Vollmer W.M., Sacks F.M., Ard J., et al. DASH-Sodium Trial Collaborative Research Group. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med 2001, 135:1019-1028.
65. He F.J., MacGregor G.A. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens 2002, 16:761-770.
66. Cook N.R., Cutler J.A., Obarzanek E., et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007, 334:885-888.
67. Pimenta E., Gaddam K.K., Oparil S., et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009, 54:475-481.
68. Taler S.J., Textor S.C., Augustine J.E. Resistant hypertension. Comparing hemodynamic management to specialist care. Hypertension 2002, 39:982-988.
69. Ray W.A., Griffin M.R., Downey W., et al. Long-term use of thiazide diuretics and risk of hip fracture. Lancet 1989, 1:687-690.
70. Wanich R., Davis J., Ross P., et al. Effects of thiazides on rates of bone mineral loss: a longitudinal study. Br Med J 1990, 310:1303-1305.
71. Ernst M.E., Carter B.L., Goerdt C.J., et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006, 47:352-358.
72. Multiple Risk Factor Intervention Trial Research Group Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 1990, 82:1616-1628.
73. Ouzan J., Perault C., Lincoff A.M., et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002, 15:333-339.
74. Dahlof B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding benzoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906.
75. Chapman N., Dobson J., Wilson S., et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839-845.
76. Nishizaka M.K., Zaman M.A., Calhoun D.A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925-930.
77. Schjoedt K.J., Rossing K., Juhl T.R., et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005, 68:2829-2836.
78. Bianchi S., Bigazzi R., Campese V.M. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled study. Am J Kidney Dis 2005, 46:45-51.
79. Chapman N., Chang C.L., Dahlof B., et al. on behalf of the ASCOT investigators. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation 2008, 118:42-48.
80. Ceral J., Solar M. Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension 2009, Blood Press, 18:74-7.
81. Black R.N., Hunter S.J., Atkinson A.B. Usefulness of the vasodilator minoxidil in resistant hypertension [research letter]. J Hypertens 2007, 25:1102-1103.
82. Townsend R.R., DiPette D.J., Goodman R., et al. Combined alpha/beta blockade versus beta 1-selective blockade in essential hypertension in black and white patients. Clin Pharmacol Ther 1990, 48:665-675.
83. Filippone J.D., Bisognano J.D. Baroreflex stimulation in the treatment of hypertension. Curr Opin Nephrol Hypertens 2007, 16:403-408.
84. Illig K.A., Levy M., Sanchez L., et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter Phase II Rheos feasibility trial. J Vasc Surg 2006, 44:1213-1218.
85. Krum H., Schlaich M., Whitbourn R., et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373:1275-1281.
86. Perez M.I., Musini V.M., Wright J.M. Pharmacological interventions for hypertensive emergencies. Cochrane Database Syst Rev 2008, 1. CD003653.
87. Perez M.I., Musini V.M. Pharmacological interventions for hypertensive emergencies: a Cochrane systematic review. J Hum Hypertens 2008, 22:596-607.